Nippon Shinyaku Co., Ltd. (4516.T) JPX

3,380.00

+86(+2.61%)

Updated at September 08 03:30PM

Currency In JPY

Nippon Shinyaku Co., Ltd.

Address

14, Nishinosho-Monguchi-cho

Kyoto, 601-8550

Japan

Phone

81 7 5321 1111

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

2213

First IPO Date

January 01, 2001

Key Executives

NameTitlePayYear Born
Mr. Takashi TakayaGM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director01960
Mr. Kazuchika TakagakiGM of Research and Development Division & Director01961
Mr. Toru NakaiPresident & Director01971
Yoko NakanishiCorporate Officer & Department Manager of Human Resources Dept.0N/A
Mr. Shouzou SanoMD of Sales & Marketing and Director01960
Mr. Takanori EdamitsuHead of Business Management & Sustainability and Director01963
Mr. Hitoshi IshizawaGM of Functional Food Division & Director01961
Hayato WadaCorporate Officer & Department Manager of Kansai Business Office0N/A
Masaya TodaHead of Licensing & Alliance Division and Corporate Officer0N/A
Manabu BeppuCorporate Officer and Head of R & D Planning and Administration Dept.0N/A

Description

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.